Shareholders that lost money on MacroGenics, Inc. Urged to Join Class Action Contact Levi Korsinsky to Learn More
MGNX Stock | USD 3.49 0.05 1.45% |
Slightly above 53% of MacroGenics' investors are presently thinking to get in. The analysis of overall sentiment of trading MacroGenics stock suggests that some investors are interested at this time. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
MacroGenics |
NEW YORK, July 31, 2024 -- Levi Korsinsky, LLP notifies investors in MacroGenics, Inc. of a class action securities lawsuit. CLASS
Read at benzinga.com
MacroGenics Fundamental Analysis
We analyze MacroGenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MacroGenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MacroGenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
MacroGenics is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MacroGenics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MacroGenics stock to make a market-neutral strategy. Peer analysis of MacroGenics could also be used in its relative valuation, which is a method of valuing MacroGenics by comparing valuation metrics with similar companies.
Peers
MacroGenics Related Equities
PTGX | Protagonist Therapeutics | 2.71 | ||||
ZNTL | Zentalis Pharmaceuticals | 0.89 | ||||
TYRA | Tyra Biosciences | 0.72 | ||||
CCCC | C4 Therapeutics | 0.26 | ||||
MOLN | Molecular Partners | 0.34 | ||||
IPSC | Century Therapeutics | 0.69 | ||||
SNDX | Syndax Pharmaceuticals | 0.71 | ||||
KZR | Kezar Life | 1.42 | ||||
EWTX | Edgewise Therapeutics | 1.53 | ||||
PHVS | Pharvaris | 2.40 | ||||
DAWN | Day One | 2.46 | ||||
MLYS | Mineralys Therapeutics, | 2.63 | ||||
ANTX | AN2 Therapeutics | 2.68 | ||||
NKTX | Nkarta | 2.94 | ||||
CGEM | Cullinan Oncology | 4.01 | ||||
GLUE | Monte Rosa | 4.44 | ||||
PMVP | Pmv Pharmaceuticals | 5.36 | ||||
PEPG | PepGen | 6.32 | ||||
INZY | Inozyme Pharma | 7.81 |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.